⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31586464 | 1.00 | — | — | |
| SCHEMBL30420491 | 0.74 | — | — | |
| SCHEMBL15579216 | 0.74 | — | — | |
| SCHEMBL2144037 | 0.74 | — | — | |
| SCHEMBL29769758 | 0.74 | — | — | |
| SCHEMBL414351 | 0.74 | — | — | |
| SCHEMBL38656555 | 0.74 | — | — | |
| SCHEMBL2303127 | 0.74 | — | — | |
| SCHEMBL8237327 | 0.72 | — | — | |
| SCHEMBL22230708 | 0.70 | USP7 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| CN-112771027-B | Lysophosphatidic acid receptor antagonists and process for preparing the same | 武汉朗来科技发展有限公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-116942663-A | Compounds for the treatment of HBV | 葛兰素史克知识产权开发有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111433206-B | Compounds of formula (I) | 葛兰素史克知识产权开发有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3912975-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912975-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| CN-112771027-A | Lysophosphatidic acid receptor antagonists and process for their preparation | 武汉朗来科技发展有限公司 | 2021-05-07 | — | — | CN | disclosed |
| WO-2020147739-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
| CN-105189505-B | Tricyclic gyrase inhibitors as antibacterial agents | 默克夏普&多梅有限公司 | 2019-03-22 | — | — | CN | disclosed |
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2723737-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
| EP-1673367-A1 | FUSED LACTAM COMPOUNDS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035523-A1 | FUSED LACTAM COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-04-21 | — | — | WO | disclosed |